[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI1674111T1 - Protitelo proti glipikanu 3 - Google Patents

Protitelo proti glipikanu 3

Info

Publication number
SI1674111T1
SI1674111T1 SI200531212T SI200531212T SI1674111T1 SI 1674111 T1 SI1674111 T1 SI 1674111T1 SI 200531212 T SI200531212 T SI 200531212T SI 200531212 T SI200531212 T SI 200531212T SI 1674111 T1 SI1674111 T1 SI 1674111T1
Authority
SI
Slovenia
Prior art keywords
antibody
glypican
disclosed
agent
cancers
Prior art date
Application number
SI200531212T
Other languages
English (en)
Inventor
Kiyotaka Nakano
Takeshi Yoshino
Jun-Ichi Nezu
Hiroyuki Tsunoda
Tomoyuki Igawa
Hiroko Konishi
Megumi Tanaka
Izumi Sugo
Shigeto Kawai
Takahiro Ishiguro
Yasuko Kinoshita
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35784028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1674111(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SI1674111T1 publication Critical patent/SI1674111T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI200531212T 2004-07-09 2005-07-08 Protitelo proti glipikanu 3 SI1674111T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004203637 2004-07-09
EP05760156A EP1674111B1 (en) 2004-07-09 2005-07-08 Anti-glypican 3 antibody
PCT/JP2005/013103 WO2006006693A1 (ja) 2004-07-09 2005-07-08 抗グリピカン３抗体

Publications (1)

Publication Number Publication Date
SI1674111T1 true SI1674111T1 (sl) 2011-02-28

Family

ID=35784028

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531212T SI1674111T1 (sl) 2004-07-09 2005-07-08 Protitelo proti glipikanu 3

Country Status (26)

Country Link
US (3) US7919086B2 (sl)
EP (4) EP2216046B1 (sl)
JP (3) JP4011100B2 (sl)
KR (2) KR101300545B1 (sl)
CN (4) CN105820249A (sl)
AT (1) ATE486610T1 (sl)
AU (1) AU2005256113B2 (sl)
BR (1) BRPI0506125B8 (sl)
CA (1) CA2544692C (sl)
CY (1) CY1111649T1 (sl)
DE (1) DE602005024502D1 (sl)
DK (1) DK1674111T3 (sl)
ES (1) ES2353967T3 (sl)
HK (1) HK1092161A1 (sl)
IL (1) IL172938A (sl)
MX (1) MXPA06002890A (sl)
MY (1) MY145073A (sl)
NO (1) NO343105B1 (sl)
NZ (2) NZ545720A (sl)
PL (1) PL1674111T3 (sl)
PT (1) PT1674111E (sl)
RU (2) RU2427588C2 (sl)
SI (1) SI1674111T1 (sl)
TW (1) TWI455946B (sl)
UA (1) UA94019C2 (sl)
WO (1) WO2006006693A1 (sl)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
KR101300545B1 (ko) * 2004-07-09 2013-09-02 츄가이 세이야꾸 가부시키가이샤 항 글리피칸 3 항체
CN101014367B (zh) 2004-08-24 2012-07-04 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法
NZ554940A (en) * 2004-10-26 2010-04-30 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody having modified sugar chain
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
JP2009523739A (ja) * 2006-01-20 2009-06-25 ウィメンズ アンド チルドレンズ ヘルス リサーチ インスティテュート インコーポレーティッド 骨の病変の処置、予防、および診断の方法
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
CN101421411B (zh) * 2006-04-13 2015-06-03 中外制药株式会社 牛磺酸转运蛋白基因
WO2008114673A1 (ja) 2007-03-15 2008-09-25 Chugai Seiyaku Kabushiki Kaisha ポリペプチドの製造方法
CN105567627B (zh) 2007-04-26 2020-09-29 中外制药株式会社 使用含高浓度氨基酸的培养基的细胞培养方法
AU2008275985B2 (en) * 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
AU2008284753B2 (en) 2007-08-07 2014-01-16 Chugai Seiyaku Kabushiki Kaisha Method of producing heterogeneous protein
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
RU2010116756A (ru) * 2007-09-28 2011-11-10 Чугаи Сейяку Кабусики Кайся (Jp) Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
JP5337043B2 (ja) 2007-10-15 2013-11-06 中外製薬株式会社 異種タンパク質を高生産する細胞の作製方法
US9683027B2 (en) 2007-10-15 2017-06-20 Chugai Seiyaku Kabushiki Kaisha Method for production of antibody
CA2703493C (en) 2007-10-24 2016-11-08 Chugai Seiyaku Kabushiki Kaisha A cell for use in production of heteroproteins and production method using the same
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2262837A4 (en) * 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009226423B2 (en) * 2008-03-17 2014-11-27 Chugai Seiyaku Kabushiki Kaisha Method for detection of liver cancer cell using anti-glypican-3 antibody
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
NZ590515A (en) 2008-07-08 2013-01-25 Geneuro Sa Therapeutic use of specific ligand in msrv associated diseases
JP5749930B2 (ja) 2008-10-28 2015-07-15 中外製薬株式会社 ペプチド含有動物細胞培養用培地
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
KR20110120891A (ko) 2009-01-15 2011-11-04 래버러토리 코포레이션 오브 아메리카 홀딩스 Ｈｅｒ-３의 측정에 의한 환자 반응의 결정 방법
ES2526519T3 (es) * 2009-01-15 2015-01-13 Laboratory Corporation Of America Holdings Métodos de determinación de la respuesta del paciente por medición de la expresión HER-2
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
MX2012001708A (es) * 2009-08-07 2012-05-22 Kyowa Hakko Kirin Co Ltd Anticuerpo humanizado anti-oligomero de amiloide b.
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
SI2609118T1 (sl) 2010-08-23 2017-05-31 The Board Of Regents, The University Of Texas System Protitelesa proti ox40 in postopki uporabe istih
NZ608318A (en) * 2010-09-02 2015-03-27 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP3434767A1 (en) 2010-11-30 2019-01-30 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP2660328A4 (en) * 2010-12-28 2016-07-13 Chugai Pharmaceutical Co Ltd ANIMAL CELL CULTURE METHOD
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用
EP3825325A3 (en) 2011-03-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
MX352229B (es) 2011-04-01 2017-11-15 Chugai Pharmaceutical Co Ltd Metodo de produccion de polipeptido recombinante.
EP2998320B1 (en) * 2011-04-19 2018-07-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
CN110680920A (zh) 2011-09-30 2020-01-14 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
KR102398736B1 (ko) 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
ES2873035T3 (es) * 2012-01-31 2021-11-03 Sbi Biotech Co Ltd Anticuerpo antifosfolipasa D4
TWI617577B (zh) 2012-02-24 2018-03-11 中外製藥股份有限公司 經ＦｃγＲＩＩＢ促進抗原消失之抗原結合分子
IN2014DN08199A (sl) 2012-03-02 2015-05-01 Vaccinex Inc
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
SG11201407972RA (en) 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
KR102358375B1 (ko) 2012-10-10 2022-02-08 추가이 세이야쿠 가부시키가이샤 개변 숙주 세포의 수립 방법
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US9790271B2 (en) 2013-01-31 2017-10-17 Vaccinex, Inc. Methods for increasing immunoglobulin A levels
WO2014159087A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
CN107460201A (zh) * 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3078744B1 (en) 2013-12-04 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
EP3088890B1 (en) * 2013-12-24 2020-09-23 Chugai Seiyaku Kabushiki Kaisha Method for measuring soluble gpc3 protein
JP6629187B2 (ja) 2014-04-07 2020-01-15 中外製薬株式会社 免疫活性化抗原結合分子
CN113933504A (zh) * 2014-05-08 2022-01-14 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
WO2015172341A1 (zh) * 2014-05-14 2015-11-19 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
US10093746B2 (en) 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
JP2017532953A (ja) 2014-09-16 2017-11-09 オバサイエンス・インコーポレイテッド 抗ｖａｓａ抗体、ならびにその産生法および使用法
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
EP3245219B1 (en) * 2015-01-16 2020-04-08 GlyP Holdings Pty Limited Glypican epitopes and uses thereof
CN104610441B (zh) * 2015-03-04 2018-02-13 首都医科大学 用于制备磷脂酰肌醇蛋白聚糖‑3(gpc3)单抗的人工半抗原、制备方法及获得的单克隆抗体
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
EP3889184A1 (en) * 2015-08-03 2021-10-06 Cafa Therapeutics Limited Antibody against glypican-3 and application thereof
CN105126123B (zh) * 2015-09-29 2018-04-03 南通大学 纳米探针的制备方法、基于天然产物单体和纳米探针的纳米药物的制备方法及应用
CN105112046A (zh) * 2015-09-29 2015-12-02 南通大学 核壳结构量子点的制备方法、靶向肿瘤标志物gpc-3的荧光纳米探针及其制备方法
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
JP6292564B2 (ja) * 2016-03-10 2018-03-14 シスメックス株式会社 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット
SG10202007025PA (en) 2016-03-14 2020-08-28 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
PL3430054T3 (pl) * 2016-03-15 2022-05-23 Chugai Seiyaku Kabushiki Kaisha Sposoby leczenia nowotworów z zastosowaniem antagonistów wiązania z osią PD-1 i przeciwciał anty-GPC3
US11046778B2 (en) * 2016-03-31 2021-06-29 Tohoku University Anti-podocalyxin antibody that targets tumor microenvironment
KR102529012B1 (ko) 2016-04-22 2023-05-09 크라제 메디컬 씨오 리미티드 세포성 면역요법을 위한 조성물 및 방법
CA3031846A1 (en) 2016-07-26 2018-02-01 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
JP7125347B2 (ja) 2016-08-22 2022-08-24 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
AU2017364818B2 (en) 2016-11-28 2024-11-21 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
JP2018093823A (ja) 2016-12-15 2018-06-21 Ｈｅａｒｔｓｅｅｄ株式会社 未分化幹細胞除去剤及び未分化幹細胞除去方法
EP3565596A4 (en) * 2017-01-05 2020-12-16 Brown University PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
NZ754830A (en) 2017-01-10 2024-10-25 Univ Yamaguchi Anti-gpc3 antibody
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
WO2018200586A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
JP7276855B2 (ja) * 2017-06-20 2023-05-18 サヴィッド・セラピューティックス株式会社 抗硫酸化グリコサミノグリカン抗体
WO2019023410A1 (en) * 2017-07-28 2019-01-31 Phanes Therapeutics, Inc. ANTI-TIM-1 ANTIBODIES AND USES THEREOF
US10766968B2 (en) 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
JP7382922B2 (ja) * 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
SG11202004627WA (en) 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Ligand-binding molecule having adjustable ligand-binding activity
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
US20210196568A1 (en) 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
EP3805112A4 (en) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha FILLING NOZZLE
EP3816182A4 (en) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
CN112469829B (zh) * 2018-07-17 2023-07-07 诺伊尔免疫生物科技株式会社 包含抗gpc3单链抗体的car
CN110760005A (zh) * 2018-07-25 2020-02-07 上海细胞治疗集团有限公司 一种靶向Glypican-3抗原的嵌合抗原受体修饰T细胞及其用途
US12077785B2 (en) 2018-08-14 2024-09-03 Sotio Biotech Inc. Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
BR112021006254A2 (pt) 2018-10-01 2021-07-27 Adicet Bio, Inc. composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos
BR112021007175A2 (pt) 2018-10-23 2021-08-10 Dragonfly Therapeutics, Inc. proteínas fundidas a fc heterodimérico
US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
WO2020190217A2 (en) * 2019-03-21 2020-09-24 Agency For Science, Technology And Research Composition
WO2020230901A1 (ja) 2019-05-15 2020-11-19 協和キリン株式会社 Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
CN113905757A (zh) 2019-06-05 2022-01-07 中外制药株式会社 抗体切割位点结合分子
WO2020246567A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド
WO2021010346A1 (ja) * 2019-07-12 2021-01-21 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
EP4007604A4 (en) * 2019-08-01 2023-07-19 R.P. Scherer Technologies, LLC ANTIBODY SPECIFIC TO GPC3 AND METHODS OF USE THEREOF
CN112390886B (zh) * 2019-08-16 2022-08-16 原启生物科技(上海)有限责任公司 一种分离的抗原结合蛋白及其用途
WO2021110095A1 (zh) * 2019-12-05 2021-06-10 上海翰森生物医药科技有限公司 抗gpc3抗体、其抗原结合片段及其医药用途
CN111116749B (zh) * 2019-12-31 2023-02-17 南京拂晓生物科技有限公司 重组的人源化gpc3抗体及其制备和应用
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
CN111909902B (zh) * 2020-06-24 2021-12-21 天津金虹生物科技开发有限公司 一种杂交瘤细胞株、单克隆抗体及其制备方法和应用、制备致敏胶乳原液的方法以及试剂盒
IL300225A (en) 2020-07-31 2023-03-01 Chugai Pharmaceutical Co Ltd A pharmaceutical composition including chimeric receptor expressing cells
WO2022057909A1 (zh) 2020-09-17 2022-03-24 上海霖羲致企业管理有限公司 双特异性重组蛋白及其用途
CN114478780A (zh) * 2020-10-23 2022-05-13 华中农业大学 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用
CN114478788A (zh) 2020-11-11 2022-05-13 高新 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
KR20220080381A (ko) * 2020-12-07 2022-06-14 (주)이노베이션바이오 Gpc3에 특이적인 항체 및 이의 용도
CN112225822B (zh) * 2020-12-14 2021-03-23 北京基因启明生物科技有限公司 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用
US11932702B2 (en) 2020-12-18 2024-03-19 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor
CN112608907B (zh) * 2020-12-18 2023-01-17 十堰市太和医院（湖北医药学院附属医院） 磷脂酰肌醇蛋白聚糖3单克隆抗体，杂交瘤细胞株和应用
EP4274853A4 (en) * 2021-01-05 2024-12-04 National Institute Of Biological Sciences, Beijing BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47
EP4279504A4 (en) * 2021-01-18 2024-11-27 Fujirebio Inc. METHOD FOR TREATING SOLUBLE SAMPLES CONTAINING GPC3 IN SOLUBLE GPC3 IMMUNOASSAYS
WO2022166876A1 (zh) * 2021-02-03 2022-08-11 江苏先声药业有限公司 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
WO2022192586A1 (en) * 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
AU2022237618A1 (en) 2021-03-17 2023-10-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
JP2024518443A (ja) * 2021-05-07 2024-05-01 センティ バイオサイエンシズ インコーポレイテッド キメラ抗原受容体および使用方法
WO2022268196A1 (zh) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 靶向gpc3的抗原结合蛋白
CN113248616B (zh) * 2021-07-07 2022-04-12 北京艺妙神州医药科技有限公司 靶向gpc3的嵌合抗原受体及其用途
EP4367141A1 (en) * 2021-07-07 2024-05-15 Triumvira Immunologics USA, Inc. Gpc3 t cell-antigen couplers and uses thereof
CN113354737B (zh) * 2021-07-20 2022-11-18 广州爱思迈生物医药科技有限公司 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
AU2022326107A1 (en) 2021-08-12 2024-03-14 Shanghai Ttm-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
WO2023034762A2 (en) * 2021-08-30 2023-03-09 Obi Pharma, Inc. Bispecific dendritic cell engager and uses thereof
EP4399230A1 (en) * 2021-09-06 2024-07-17 Nanjing Legend Biotech Co., Ltd. Anti-gpc3 chimeric antigen receptor and methods of use thereof
IL311956A (en) 2021-10-08 2024-06-01 Chugai Pharmaceutical Co Ltd Method for preparing prefilled syringe formulation
KR20230060546A (ko) 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
CA3237201A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
JP2024540536A (ja) * 2021-11-19 2024-10-31 アーディアジェン コーポレーション Ｇｐｃ３結合剤、そのコンジュゲートおよびその使用方法
WO2023174401A1 (zh) 2022-03-18 2023-09-21 映恩生物制药（苏州）有限公司 Gpc3抗体药物偶联物及其用途
AU2023262861A1 (en) 2022-04-26 2024-11-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical-preparation-containing syringe equipped with filter
WO2023229013A1 (ja) 2022-05-27 2023-11-30 北京天一方生物科技▲発▼展有限公司 ＩＬ－１２ｐ７０を恒常的に産生する増殖性ミエロイド細胞の製造方法
WO2024076375A1 (en) * 2022-10-07 2024-04-11 Jecho Laboratories, Inc. Glypican 3 antibody and related methods
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用
CN116333172B (zh) * 2023-05-04 2024-02-09 广州百暨基因科技有限公司 融合蛋白及其应用
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0242355A (ja) 1988-08-02 1990-02-13 Hitachi Constr Mach Co Ltd 超音波検査装置
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
JPH04336051A (ja) 1991-05-10 1992-11-24 Toshiba Corp 超音波診断装置
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0640094A1 (en) * 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
AU3272695A (en) * 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
IL129164A (en) 1996-09-26 2007-05-15 Chugai Pharmaceutical Co Ltd An antibody against peptides associated with human parathyroid hormone
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
KR100473836B1 (ko) * 1997-10-03 2005-03-07 츄가이 세이야꾸 가부시키가이샤 천연 인간형화 항체
JPH11118775A (ja) 1997-10-09 1999-04-30 Canon Inc 超音波検査装置
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP3606132B2 (ja) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 超音波探傷方法およびその装置
JP2002048867A (ja) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd 音響探査装置
EP1319044B1 (en) 2000-09-12 2007-06-06 Union Carbide Chemicals & Plastics Technology Corporation Polymer composites containing ethylene oxide copolymers
EP2314686B2 (en) 2000-10-06 2023-06-21 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
JP4336051B2 (ja) 2001-01-31 2009-09-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信端末、発呼制限方法及びプログラム
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US20020194747A1 (en) * 2001-06-21 2002-12-26 Passke Joel L. Footwear with bladder filter
ES2353335T3 (es) 2001-06-22 2011-03-01 Chugai Seiyaku Kabushiki Kaisha Inhibidores del crecimiento celular que contienen anticuerpo anti-glipicano 3.
JP2005524379A (ja) * 2001-08-03 2005-08-18 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性の増強を伴う抗体グリコシル化改変体
JP3961359B2 (ja) 2002-07-18 2007-08-22 株式会社東芝 超音波画像化装置
US7421900B2 (en) * 2001-11-14 2008-09-09 Kabushiki Kaisha Toshiba Ultrasonograph, ultrasonic transducer, examining instrument, and ultrasonographing device
JP4087098B2 (ja) 2001-11-14 2008-05-14 株式会社東芝 超音波検査装置
WO2003057881A1 (fr) 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Procede de stabilisation d'une proteine
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
BRPI0311233B8 (pt) 2002-05-23 2021-07-27 Sunnybrook And Womens College Health Sciences Centre métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
AU2002328429A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
JP4090345B2 (ja) 2002-12-24 2008-05-28 株式会社グラノプト 液相結晶成長法
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
EP1671645A4 (en) 2003-09-04 2007-07-25 Chugai Pharmaceutical Co Ltd REMEDIES AND MEDIUM FOR DETECTING GALLENGIFT CANCER
ITBO20040008U1 (it) 2004-02-03 2004-05-03 Tonazzi S R L Macchina per il riempimento e la chiusura di tubetti
KR101300545B1 (ko) 2004-07-09 2013-09-02 츄가이 세이야꾸 가부시키가이샤 항 글리피칸 3 항체
JP2008510008A (ja) * 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド 抗体依存性細胞性細胞傷害活性が増強されたインテグリンアンタゴニスト
CN101014367B (zh) 2004-08-24 2012-07-04 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法
NZ554940A (en) * 2004-10-26 2010-04-30 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody having modified sugar chain
WO2006067847A1 (ja) * 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) * 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
AU2009226423B2 (en) * 2008-03-17 2014-11-27 Chugai Seiyaku Kabushiki Kaisha Method for detection of liver cancer cell using anti-glypican-3 antibody
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

Also Published As

Publication number Publication date
CN1842540A (zh) 2006-10-04
CA2544692C (en) 2014-04-01
NZ579543A (en) 2011-07-29
EP2898897A3 (en) 2015-10-14
BRPI0506125B8 (pt) 2021-05-25
EP2216046A3 (en) 2010-12-22
PT1674111E (pt) 2010-12-15
ATE486610T1 (de) 2010-11-15
RU2611751C2 (ru) 2017-02-28
EP2216046B1 (en) 2014-03-12
RU2427588C2 (ru) 2011-08-27
CN1842540B (zh) 2012-07-04
MXPA06002890A (es) 2006-06-05
NO343105B1 (no) 2018-11-05
JP4011100B2 (ja) 2007-11-21
NZ545720A (en) 2010-01-29
EP1674111A4 (en) 2008-03-19
EP1674111A1 (en) 2006-06-28
CA2544692A1 (en) 2006-01-19
JP5715603B2 (ja) 2015-05-07
DE602005024502D1 (de) 2010-12-16
KR101300545B1 (ko) 2013-09-02
KR20070034448A (ko) 2007-03-28
US20070190599A1 (en) 2007-08-16
CN105820249A (zh) 2016-08-03
JP2009232848A (ja) 2009-10-15
BRPI0506125A (pt) 2006-10-24
CN111925445A (zh) 2020-11-13
EP2314317A3 (en) 2011-06-29
RU2011115845A (ru) 2012-10-27
RU2006104842A (ru) 2007-08-27
CN102702353A (zh) 2012-10-03
KR20130014698A (ko) 2013-02-08
EP2898897A2 (en) 2015-07-29
ES2353967T3 (es) 2011-03-08
WO2006006693A1 (ja) 2006-01-19
JP2013039131A (ja) 2013-02-28
US20150259417A1 (en) 2015-09-17
HK1092161A1 (en) 2007-02-02
PL1674111T3 (pl) 2011-04-29
IL172938A0 (en) 2006-06-11
IL172938A (en) 2013-09-30
TWI455946B (zh) 2014-10-11
EP1674111B1 (en) 2010-11-03
AU2005256113B2 (en) 2011-02-10
BRPI0506125B1 (pt) 2019-10-15
KR101413402B1 (ko) 2014-06-27
US20100248359A1 (en) 2010-09-30
TW200617022A (en) 2006-06-01
AU2005256113A8 (en) 2008-09-11
EP2216046A2 (en) 2010-08-11
JPWO2006006693A1 (ja) 2008-05-01
EP2314317A2 (en) 2011-04-27
MY145073A (en) 2011-12-15
AU2005256113A1 (en) 2006-03-30
US7919086B2 (en) 2011-04-05
UA94019C2 (ru) 2011-04-11
DK1674111T3 (da) 2011-02-07
CY1111649T1 (el) 2015-10-07
NO20063539L (no) 2007-01-09

Similar Documents

Publication Publication Date Title
HK1092161A1 (en) Anti-glypican 3 antibody
EP2620450A3 (en) Anti-CTLA-4 antibody compositions
EP2345671B8 (en) Optimized fc variants and methods for their generation
WO2004099249A3 (en) Optimized fc variants and methods for their generation
MX2009004170A (es) Materiales y metodos para inmunoglicoproteinas mejoradas.
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
EP2270045B8 (en) Antibodies against Clostridium difficile toxins and uses thereof
WO2006012646A3 (en) Amacr cancer markers
MY150643A (en) Methods and compositions for targeting hepsin
WO2009030770A3 (en) Methods and tools for prognosis of cancer in er- patients
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
NO20082852L (no) Faramsoytisk blanding samt bruk av alfa-hydroksy karbonylforbindelser som reduksjonsmidler
WO2007143004A3 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
EP1773883A4 (en) PRODUCTION OF ANTICANCER ANTIBODIES USING MASKED CANCER CELLS AS IMMUNOGENS
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
WO2003079974A3 (en) Integrin ligand
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
ZA200906225B (en) Cancer disease modifying antibody 010207-01 produced by hybridoma cell line AR51A630.3
白岩孝行 et al. The Amur Okhotsk Project
UA93875C2 (ru) Выделенное химерическое или гуманизированное антитело, kotopoe специфически связывается c полипептидом tat10772 (ca125)
ITTO20020129V0 (it) Aletta parasole per veicoli.
CA115679S (en) Sun shield for vehicles
ZA200301901B (en) Fuel additive.